Safety profile of sublingual immunotherapy.
Sublingual immunotherapy (SLIT) was proposed for clinical practice about 20 years ago with the main aim of improving the safety and avoiding the adverse effects of traditional treatment for allergic airways disease. To date, 32 randomized controlled trials and 6 postmarketing surveys have been published that provide a robust documentation of the safety profile of the treatment.Looking at the randomized trials it emerges that the more frequent adverse event of SLIT is oral itching or swelling, followed by gastrointestinal complaints. These adverse events are invariably described as mild and easily managed by adjusting the dose. Relevant systemic adverse events (asthma, urticaria, angioedema) occur sporadically and, with the exception of oral/gastrointestinal adverse events, the incidence of adverse events seems not to differ between the placebo and active groups. The safety profile of SLIT does not differ between adults and children.The postmarketing surveys consistently show that the incidence of adverse events associated with SLIT is less than 10%, corresponding to less than 1 adverse event per 1000 doses, and is thus quite superior to the safety profile of subcutaneous immunotherapy. Of note, the most recent data show that the rate of adverse events with SLIT is not increased in children below the age of 5 years.
Passalacqua
Giovanni
G
Department of Internal Medicine, Allergy and Respiratory Diseases, University of Genoa, Genoa, Italy.
Guerra
Laura
L
Fumagalli
Federica
F
Canonica
Giorgio Walter
GW
D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage; D001249:Asthma / Q000188:drug therapy; D003888:Desensitization, Immunologic; D006801:Humans; D063729:Sublingual Immunotherapy; D014581:Urticaria / Q000139:chemically induced
D000485:Allergens